Tezepelumab reduces oral corticosteroid use in severe asthma patients

Tezepelumab significantly reduced oral corticosteroid use in severe asthma patients in an open-label trial. Nearly all participants achieved a low daily OCS dose or discontinued them entirely while maintaining asthma control after 52 weeks of treatment. An accompanying editorial cautioned that placebo effects might have influenced the trial's positive outcomes, suggesting further controlled studies are needed.